Our latest research on Multiple System Atrophy (MSA) has not only been published in the prestigious journal Brain, but it has also captured national attention, being featured in the New Zealand Herald. This recognition underscores the significance of our findings and highlights the growing impact of MSA research in New Zealand. Imagine a disease so aggressive that within a few short years, vibrant, active individuals are reduced to a state of near-total immobility, trapped in their own bodies, reliant on full-time care. This is the devastating reality of Multiple System Atrophy (MSA), a rare and rapidly progressing neurodegenerative disorder that cruelly robs people of their independence and dignity. Now, groundbreaking research led by Dr Birger Victor Dieriks from the University of Auckland in collaboration with Prof Glenda Halliday from the University of Sydney is challenging long-held beliefs about what drives this relentless disease, offering new hope for understanding—and eventually combating—MSA.
Published in the prestigious journal Brain, the study "Neuronal α-synuclein toxicity is the key driver of neurodegeneration in multiple system atrophy" presents a paradigm-shifting discovery. For decades, scientists believed that the primary culprits behind MSA's devastating effects were oligodendrocytes, the cells responsible for producing myelin, the protective sheath around nerve fibres. These cells were known to accumulate clumps of a protein called α-synuclein, forming structures known as glial cytoplasmic inclusions (GCIs). However, while these inclusions are a hallmark of MSA, they didn’t explain the rapid and widespread neuronal death seen in patients.
Dr Dieriks and his team have now uncovered that the real driver of MSA's aggressive neurodegeneration lies within the neurons themselves. Using cutting-edge super-resolution microscopy and advanced α-synuclein antibodies, the researchers discovered that α-synuclein aggregates penetrate the nuclei of neurons in MSA patients. Once inside, these toxic protein clumps disrupt the 3D organisation of the nucleus, leading to its destruction and, ultimately, the death of the neuron.
“This finding breaks with established dogma,” says Dr Dieriks. “For years, the focus has been on the oligodendrocytes because that’s where most of the α-synuclein clumps were found. But our research shows that it’s the neuronal α-synuclein aggregates that are the real killers, and this explains why MSA progresses so much faster than similar diseases like Parkinson’s.”
A Disease Often Mistaken, But Far More Ruthless
MSA is often misdiagnosed as Parkinson’s disease due to overlapping symptoms like muscle rigidity, balance issues, and tremors. However, MSA progresses at a much more alarming rate. While Parkinson’s patients can live for decades with the disease, MSA patients typically survive only 4 to 10 years after the onset of symptoms. The rapid decline often leaves patients bedridden and dependent on full-time care, with many losing the ability to speak or move.
Unlike Parkinson’s, where the loss of dopamine-producing neurons is the primary cause of symptoms, MSA is characterised by widespread failure in multiple brain systems, including those that control movement, balance, and autonomic functions like blood pressure and digestion. Until now, the reasons behind this extensive neuronal loss were poorly understood.
The Double Threat of α-Synuclein Aggregates
The study didn’t just reveal that neurons are being targeted; it also uncovered two distinct types of α-synuclein aggregates in MSA—one in oligodendrocytes and another in neurons. The neuronal aggregates are more resistant to breakdown and significantly more toxic than those found in oligodendrocytes. This discovery is crucial because it suggests that therapies aimed at targeting α-synuclein in oligodendrocytes might not be effective in halting the disease's progression.
“The α-synuclein aggregates in neurons are like a double-edged sword,’ says Dr. James Wiseman, who performed the lab work and is a co-author of the study. ‘Not only do they resist the body’s attempts to clear them out, but they also invade the very control centre of the neuron—the nucleus—causing catastrophic damage.”
This invasion leads to the destruction of the nuclear envelope, a protective barrier that maintains the integrity of the neuron’s genetic material. The researchers observed significant structural damage, including the loss of Lamin integrity, a key component of the nuclear structure. Once this barrier is compromised, the neuron’s ability to function and survive is irreversibly damaged.
Shifting the Focus: A New Direction for MSA Research
These findings are more than just a scientific breakthrough; they represent a potential turning point in the fight against MSA. By identifying neurons as the primary victims of α-synuclein toxicity, researchers can now focus on developing treatments that specifically target neuronal aggregates. This could pave the way for new therapies to protect neurons from α-synuclein invasion or enhance the cell’s ability to clear these toxic proteins before they cause irreversible damage.
The study also proposes a reclassification of MSA as a neuronal nuclear and oligodendroglial α-synucleinopathy, to better reflect the distinct pathological processes occurring in the disease. This new understanding could lead to more accurate diagnoses and, ultimately, more effective treatments.
A Unique Contribution from New Zealand
What makes this research even more remarkable is that it comes from the only group in New Zealand dedicated to studying this horrendous disease. Dr Dieriks and his team at the University of Auckland, together with Prof Halliday from The University of Sydney, have carved out a niche in the global scientific community, significantly contributing to our understanding of MSA despite limited resources.
“Being the only group in New Zealand working on MSA is both a challenge and an opportunity,” says Dr Dieriks. “It means we have to be innovative in our approach, but it also allows us to collaborate closely with international experts, like our colleagues at the University of Sydney, to push the boundaries of what we know about this disease.”
Looking Ahead: Hope on the Horizon
While there is still much work to be done, this study offers a glimmer of hope for MSA patients and their families. Understanding the true drivers of neurodegeneration in MSA is the first step towards developing targeted therapies that could slow, or even halt, the disease’s progression.
For now, the fight against MSA continues, but thanks to the groundbreaking work of Dr Dieriks and his team, we are one step closer to unravelling the mysteries of this devastating disease. And with each new discovery, the hope grows that one day, MSA will no longer be a life sentence but a condition that can be managed—or even cured. Dr Victor Dieriks
Comments